Raloxifene Hydrochloride Bodybuilding Masteron Steroid 82640 04 8

Bodybuilding Masteron Steroid Light Yellow / Almost White Raloxifene Hydrochloride

Quick Detail:

Raloxifene Hydrochloride
CAS: 82640-04-8
Purity: 99.6%
Molecular formula: C28H28ClNO4S
Molecular Weight: 510.04
Appearance: Light yellow solid
Flash Point: 394.2 °C
Enthalpy of Vaporization: 110.08 kJ/mol
Boiling Point: 728.2 °C at 760 mmHg
Vapour Pressure: 6.46E-22 mmHg at 25 °C
Specification: USP30/BP2005
Payment:T/T, and
Delivery:Within 24hours After Your Payment
Express: EMS, DHL, FedEx, etc(door-to-door)

Description:

Raloxifene is a selective estrogen receptor modulator (SERM); acts as an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. May have efficacy against estrogen-sensitive cancers.
The usual adult dose is one tablet (37.5 mg) daily, administered before breakfast or 1-2 hours after breakfast. Bodybuilder dosage recommendations are consistent with those of patients, and should be individualized to obtain an adequate response with the lowest effective dose. For some patients or bodybuilders half a tablet (18.75 mg) daily may be adequate, while others might take half a dose twice daily. Raloxifene is a selective estrogen receptor modulator (SERM); acts as an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. May have efficacy against estrogen-sensitive cancers.

Effects:

1) Raloxifene Hcl used to prevent & treat osteoporosis in women who have undergone menopause.
2) Raloxifene Hcl used to decrease the risk of developing invasive breast cancer in women who are at high risk of developing this type of cancer or who have osteoporosis. Raloxifene Hcl cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition.
3) Raloxifene Hcl prevents and treats osteoporosis by mimicking the effects of estrogen to increase the density (thickness) of bone.
4) Raloxifene Hcl decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue, which may stop the development of tumors that need estrogen to grow.

Usage:

Evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women. It is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density.
Because of the different types of dosage form and specifications. please read carefully instructions or follow the doctor's advice.

Why you choose us:

1. Quality : we deal with steroid relevant products over 10 years, and have many stable customers from all over the world. All of them witness our products' quality.
2. Package : Different package for different customs results in high rate of customs clearance.
3. Delivery: No matter where you are from, safe delivery will be finished within 7 working days.
4. Guarantee: Reship policy will be shown to you before your order. The more you buy, the more discounts you will enjoy.

Application:

Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. It is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density.For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate.

Raloxifene is used to prevent and treat bone loss (osteoporosis) in women after menopause. Maintaining strong bones by slowing bone loss helps to reduce the risk of fractures.

Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive) in women after menopause.

May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated.

Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).

Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.

Related products: